Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature.

Abstract

Necrobiotic xanthogranuloma (NXG) was first described in 1980 by Kossard and Winkelmann in an article in which they discussed 8 patients with xanthomatous plaques who were noted to have monoclonal gammopathy, predominantly of the Ig(immunoglobulin)G-κ type.(1) Since then more than 50 patients with this disorder have been described, with approximately 80% of them having an associated monoclonal gammopathy. We describe the first case, to our knowledge, of NXG with associated monoclonal gammopathy treated with thalidomide plus dexamethasone, achieving complete resolution of the skin lesions and sustaining response more than 3 years after treatment.

• Authors: Yvonne Efebera, Elizabeth Blanchard, Charles Allam, Andrew Han, Saem Lee, Nikhil Munshi
• Journal: Clinical lymphoma, myeloma & leukemia (Clin Lymphoma Myeloma Leuk) Vol. 11 Issue 3 Pg. 298-302 (Jun 2011) ISSN: 2152-2669 [Electronic] United States
• PMID: 21658660 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: Copyright © 2011 Elsevier Inc. All rights reserved.

Chemical References

• Immunosuppressive Agents
• Thalidomide
• Dexamethasone

Topics

• Aged
• Dexamethasone (adverse effects, therapeutic use)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Male
• Necrobiotic Xanthogranuloma (complications, drug therapy, immunology, pathology)
• Paraproteinemias (complications, drug therapy, immunology)
• Skin (pathology)
• Thalidomide (adverse effects, therapeutic use)
• Treatment Outcome